Septerna (NASDAQ:SEPN) Shares Up 7.7% – Still a Buy?

Septerna, Inc. (NASDAQ:SEPN)’s stock price rose 7.7% during mid-day trading on Friday . The stock traded as high as $23.09 and last traded at $23.00. Approximately 38,381 shares were traded during trading, a decline of 65% from the average daily volume of 109,190 shares. The stock had previously closed at $21.35.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Cantor Fitzgerald started coverage on Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $50.00 price target for the company. TD Cowen started coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued a “buy” rating for the company. Wells Fargo & Company began coverage on shares of Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $43.00 price objective on the stock. Finally, JPMorgan Chase & Co. began coverage on shares of Septerna in a research note on Tuesday, November 19th. They set an “overweight” rating and a $38.00 price target on the stock.

Septerna Trading Up 8.5 %

The firm has a fifty day moving average price of $23.70.

Insider Buying and Selling

In other news, major shareholder Rock Ventures V. L.P. Third acquired 370,500 shares of the business’s stock in a transaction dated Monday, October 28th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $6,669,000.00. Following the acquisition, the insider now owns 6,215,591 shares of the company’s stock, valued at $111,880,638. This trade represents a 6.34 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.